CTKB's CTO Ming Yan Sells Shares as Institutions Adjust Holdings
CTKB's Chief Technology Officer Ming Yan sold 135,892 shares on June 12, 2026.
Key Points
- On June 12, 2026, CTKB's Chief Technology Officer Ming Yan sold 135,892 shares.
- Shares of CTKB traded near $3.93, with significant institutional activity from BlackRock and Millennium Management.
- Analysts from Stephens & Co. and Morgan Stanley maintained their ratings with price targets of $4.75 and $5.5, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
CTKB's Chief Technology Officer, Ming Yan, sold 135,892 shares on June 12, 2026. This move comes amid a period of notable institutional trading activity around the company's stock.
Other Institutional Activity in CTKB
Several institutional investors have been active in CTKB. BlackRock, Inc. reduced its holdings by 165,759 shares, leaving it with 17,007,269 shares valued at approximately $74.3 million. Topline Capital Management, LLC also cut back, selling 377,985 shares to hold 7,064,481 shares worth about $30.9 million. On the other hand, Millennium Management LLC significantly increased its position, adding 1,539,351 shares to reach a total of 6,291,798 shares, valued at $27.5 million. Boston Partners also expanded its stake by 794,464 shares, ending with 5,802,773 shares valued at $25.4 million.
Cytek Biosciences, Inc. Stock Down 16.0%
Shares of CTKB traded near $3.93 recently. The stock has seen varied interest from institutional investors, reflecting diverse strategies around its valuation and market position.
Insider Buying and Selling at Cytek Biosciences, Inc.
In addition to Ming Yan's transaction, several other insiders were active. Vera Imper purchased 43,973 shares on June 10, 2026. Richard Chin, Michael Holder, and Deborah Neff each bought 18,261 shares on the same day. Michael Holder made an additional purchase of 43,973 shares.
Analysts Set New Price Targets
Analysts have been maintaining their positions on CTKB. On May 13, 2026, Stephens & Co. reiterated its 'buy' rating with a $4.75 price target. Morgan Stanley maintained a 'hold' rating with a $5.5 target on May 12, 2026. Earlier in the year, TD Cowen also kept a 'buy' rating with a $5.0 target.
About CTKB
CTKB operates in a dynamic sector, focusing on innovative solutions and technologies. The company is known for its commitment to developing and enhancing products that meet evolving market demands. CTKB's efforts are led by a team of experienced professionals dedicated to maintaining the company's competitive edge in the industry.
Bottom Line
The recent insider sale by Ming Yan and the varying institutional adjustments highlight the dynamic movements in CTKB's stock. Investors often watch these activities closely to gauge market sentiment and potential future performance. As always, it's important to remember that insider and institutional transactions are historical data and may not reflect current positions or future actions.
Get Cytek Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CTKB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.